3-(1,1-dimethylheptyl)-1-hydroxy-9-methyl-6H-dibenzo[b,d]pyran-6-one | 194714-93-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 3-(1,1-dimethylheptyl)-1-hydroxy-9-methyl-6H-dibenzo[b,d]pyran-6-one
• 英文别名: 3-(1,1-Dimethyl-heptyl)-1-hydroxy-9-methyl-benzo[c]chromen-6-one；1-hydroxy-9-methyl-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one
• CAS: 194714-93-7
• 化学式: C₂₃H₂₈O₃
• 分子量: 352.474
• InChiKey: WFUIRMQOOAUKII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲基碘化镁 、 3-(1,1-dimethylheptyl)-1-hydroxy-9-methyl-6H-dibenzo[b,d]pyran-6-one 以 四氢呋喃 、 乙醚 为溶剂， 反应 1.5h， 生成 2-[2-(2-hydroxypropan-2-yl)-5-methylphenyl]-5-(2-methyloctan-2-yl)benzene-1,3-diol
  参考文献：
  名称：

  大麻内酯：具有外周镇痛活性的一类新型的CB2选择性激动剂。

  摘要：

  CB2大麻素受体的鉴定为开发治疗上有用的大麻素能分子提供了新的靶标。我们合成了对这种受体具有高亲和力和选择性的苯并[c] chromen-6-one类似物。这些新型化合物在结构上与大麻素（6,6,9-三甲基-3-戊基-6 H-苯并[c] chromen-1-ol）有关，后者是大麻的天然成分，具有适度的CB2选择性。新的选择性激动剂的关键药理学特性包括大麻素三环结构上的3-（1'，1'-二甲基庚基）侧链和6-氧代基团，这些化合物将这类化合物表征为“大麻内酯”。我们的结果表明六元内酯药效团对CB2受体的选择性至关重要。9-羟基类似物5（AM1714）表现出对CB2受体具有490倍的最佳受体亚型选择性和亚纳摩尔亲和力，而9-甲氧基类似物4b（AM1710）具有54倍的CB2选择性。X射线晶体学和分子建模显示大麻内酯具有平面环构象。体外试验表明，新化合物是CB2激动剂，而大麻内酯4b和5的体内试验发现它们具有有效的外周镇痛活性。

  DOI：

  10.1021/jm070441u
• 作为产物：
  描述：

  5-(1,1-二甲基庚基)间苯二酚 在 sulfur 、 三氯氧磷 作用下， 以 苯 为溶剂， 反应 7.0h， 生成 3-(1,1-dimethylheptyl)-1-hydroxy-9-methyl-6H-dibenzo[b,d]pyran-6-one
  参考文献：
  名称：

  Cannabinol Derivatives:  Binding to Cannabinoid Receptors and Inhibition of Adenylylcyclase

  摘要：

  Several derivatives of cannabinol anti the 1,1-dimethylheptyl homolog (DMM) of cannabinol were prepared and assayed for binding to the brain and the peripheral cannabinoid receptors (CB1 and CB2), as well as for activation of CB1- and CB2-mediated inhibition of adenylylcyclase. The DMH derivatives were much more potent than the pentyl (i.e., cannabinol) derivatives. 11-Hydroxycannabinol (4a) was found to bind potently to both CB1 and CB2 (K-i values of 38.0 +/- 7.2 and 26.6 +/- 5.5 nM, respectively) and to inhibit CB1-mediated adenylylcyclase with an EC50 of 58.1 +/- 6.2 nM but to cause only 20% inhibition of CB2-mediated adenylylcyclase at 10 mu M. It behaves as a specific, though not potent, CB2 antagonist. 11-Hydroxycannabinol-DMH (4b) is a very potent agonist for both CB1 and CB2 (K-i values of 100 +/- 50 and 200 +/- 40 pM; EC50 of adenylylcyclase inhibition 56.2 +/- 4.2 and 207.5 +/- 27.8 pM, respectively).

  DOI：

  10.1021/jm970126f

文献信息

• Cannabilactones: A Novel Class of CB2 Selective Agonists with Peripheral Analgesic Activity
  作者：Atmaram D. Khanolkar、Dai Lu、Mohab Ibrahim、Richard I. Duclos, Jr.、Ganesh A. Thakur、T. Phillip Malan, Jr.、Frank Porreca、Vijayabaskar Veerappan、Xiaoyu Tian、Clifford George、Damon A. Parrish、Demetris P. Papahatjis、Alexandros Makriyannis

  DOI：10.1021/jm070441u

  日期：2007.12.27

  The identification of the CB2 cannabinoid receptor has provided a novel target for the development of therapeutically useful cannabinergic molecules. We have synthesized benzo[ c]chromen-6-one analogs possessing high affinity and selectivity for this receptor. These novel compounds are structurally related to cannabinol (6,6,9-trimethyl-3-pentyl-6 H-benzo[ c]chromen-1-ol), a natural constituent of

  CB2大麻素受体的鉴定为开发治疗上有用的大麻素能分子提供了新的靶标。我们合成了对这种受体具有高亲和力和选择性的苯并[c] chromen-6-one类似物。这些新型化合物在结构上与大麻素（6,6,9-三甲基-3-戊基-6 H-苯并[c] chromen-1-ol）有关，后者是大麻的天然成分，具有适度的CB2选择性。新的选择性激动剂的关键药理学特性包括大麻素三环结构上的3-（1'，1'-二甲基庚基）侧链和6-氧代基团，这些化合物将这类化合物表征为“大麻内酯”。我们的结果表明六元内酯药效团对CB2受体的选择性至关重要。9-羟基类似物5（AM1714）表现出对CB2受体具有490倍的最佳受体亚型选择性和亚纳摩尔亲和力，而9-甲氧基类似物4b（AM1710）具有54倍的CB2选择性。X射线晶体学和分子建模显示大麻内酯具有平面环构象。体外试验表明，新化合物是CB2激动剂，而大麻内酯4b和5的体内试验发现它们具有有效的外周镇痛活性。
• Cannabinol Derivatives:  Binding to Cannabinoid Receptors and Inhibition of Adenylylcyclase
  作者：Man-Hee Rhee、Zvi Vogel、Jacob Barg、Michael Bayewitch、Rivka Levy、Lumir Hanuš、Aviva Breuer、Raphael Mechoulam

  DOI：10.1021/jm970126f

  日期：1997.9.1

  Several derivatives of cannabinol anti the 1,1-dimethylheptyl homolog (DMM) of cannabinol were prepared and assayed for binding to the brain and the peripheral cannabinoid receptors (CB1 and CB2), as well as for activation of CB1- and CB2-mediated inhibition of adenylylcyclase. The DMH derivatives were much more potent than the pentyl (i.e., cannabinol) derivatives. 11-Hydroxycannabinol (4a) was found to bind potently to both CB1 and CB2 (K-i values of 38.0 +/- 7.2 and 26.6 +/- 5.5 nM, respectively) and to inhibit CB1-mediated adenylylcyclase with an EC50 of 58.1 +/- 6.2 nM but to cause only 20% inhibition of CB2-mediated adenylylcyclase at 10 mu M. It behaves as a specific, though not potent, CB2 antagonist. 11-Hydroxycannabinol-DMH (4b) is a very potent agonist for both CB1 and CB2 (K-i values of 100 +/- 50 and 200 +/- 40 pM; EC50 of adenylylcyclase inhibition 56.2 +/- 4.2 and 207.5 +/- 27.8 pM, respectively).